Psychedelic Medicine Association

Our October webinar, Navigating Legal Boundaries: Discussing and Referring Patients to Psychedelic Therapies, is happening this Thursday, October 24th! This webinar is open to public attendance. Register: https://lnkd.in/gB-hvmXM The availability of psychedelic medicine varies widely depending on what country, state, and city a patient lives in—and so as practitioners, it can be difficult to know what’s legally available when evaluating which therapeutics may benefit your patients. What makes things even more confusing is that for the widely available legal psychedelics, namely ketamine, there are no currently established standards for whether ketamine treatments should include a therapeutic component, and, if so, what certification that therapist should have. So you may have questions, like, “How can I legally discuss potentially illegal substances with my patients?” and “How can I refer to a ketamine clinic or a clinical trial and protect both my patient and myself?” This month we are truly fortunate to have three attorneys who are well-versed in these areas to help answer some of your pressing legal questions, including: • Whether is it legal to discuss psychedelic medicines with patients if those substances are currently illegal • Whether referring to off-label therapies puts you in any legal danger • How to best protect yourself from malpractice claims when discussing and referring to psychedelic therapeutics ...and much more! Panelists joining for this event are: Kimberly Chew, Esq. | Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group Karen Luong, Esq. | Partner, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group Natasha Sumner, Esq. | Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly! So please join us for this live panel discussion on Thursday, October 24th at 5 pm Pacific, 8 pm Eastern!

The Psychedelic Medicine Association Illinois Chapter is hosting an exciting event on pioneering psychedelic therapy in Illinois—and it is open to the public! This Monday, October 14th, you have the opportunity to meet State Senator Ventura, Representative Ford, and Jean Lacy, the author of the Illinois CURE Act. Learn more about HB1, its impact on healthcare, and how the medical community can unite to advocate for change. Register: https://lnkd.in/grXT7ykM

We're very excited to announce this month's webinar, which we are opening to public attendance! Navigating Legal Boundaries: Discussing and Referring Patients to Psychedelic Therapies. Register: https://lnkd.in/gB-hvmXM The availability of psychedelic medicine varies widely depending on what country, state, and city a patient lives in—and so as practitioners, it can be difficult to know what’s legally available when evaluating which therapeutics may benefit your patients. What makes things even more confusing is that for the widely available legal psychedelics, namely ketamine, there are no currently established standards for whether ketamine treatments should include a therapeutic component, and, if so, what certification that therapist should have. So you may have questions, like, “How can I legally discuss potentially illegal substances with my patients?” and “How can I refer to a ketamine clinic or a clinical trial and protect both my patient and myself?” This month we are truly fortunate to have three attorneys who are well-versed in these areas to help answer some of your pressing legal questions, including: • Whether is it legal to discuss psychedelic medicines with patients if those substances are currently illegal • Whether referring to off-label therapies puts you in any legal danger • How to best protect yourself from malpractice claims when discussing and referring to psychedelic therapeutics ...and much more! Panelists joining for this event are: Kimberly Chew, Esq. | Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group Karen Luong, Esq. | Partner, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group Natasha Sumner, Esq. | Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly! So please join us for this live panel discussion on Thursday, October 24th at 5 pm Pacific, 8 pm Eastern!

The fall edition of the Psychedelic Medicine Association journal club is happening tomorrow! We will be discussing “The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training.” Register: https://lnkd.in/gTfaZUNp

The correct answer is #mescaline! 45% answered correctly.

We're very excited to be hosting the next Psychedelic Medicine Association journal club this month! We will be discussing “The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training.” Register: https://lnkd.in/gTfaZUNp At the Psychedelic Medicine Association, we’re always looking for ways to provide you even more value—both in education on psychedelics and in networking with your fellow members. And we figured a great way to do both at the same time was to start the Psychedelic Medicine Journal Club! As many of you may have experienced during school or residency, a journal club is a gathering where all attendees read the same journal article and discuss it in-depth to provide an even greater understanding of the material—all while getting to know each other even better). This month’s journal club will be led by Psychedelic Medicine Association team member Jared Morningstar, and the article we will be discussing is “The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training.” We’ll use this article as a jumping-off point for discussing the topic of first-hand psychedelic experiences in the context of training for psychedelic-assisted therapists. This will be an interactive format where everyone is encouraged to turn on their camera and share your thoughts on the article—as well as meet your fellow PMA members! So please join us for this live journal club discussion on Thursday, September 26th at 5 pm Pacific, 8 pm Eastern. Register: https://lnkd.in/gTfaZUNp

#Psychedelic knowledge check! In 1954, Aldous Huxley published the Doors of Perception detailing his experience with this psychedelic compound. We'll reveal the answer next Tuesday!

The correct answer is Walter Pahnke! 48% answered correctly.

Did you know the Psychedelic Medicine Association has local chapters? Join today to network and exchange ideas with your local psychedelic-informed colleagues! Cheers to the Iowa chapter for hosting this informative monthly event!

#Psychedelic knowledge check! Taking place April 20th 1962, the Good Friday #Experiment was a double-blind Harvard Divinity School study of drugs and the mystical experience conducted by this researcher with assistance from Ram Dass and Timothy Leary. We'll reveal the answer next Tuesday!